Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03552757 · ClinicalTrials.gov registry record · Phase 3
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
A Phase 3 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,210
- Enrollment target
- 20
- Study locations
NCT03552757: Completed Phase 3 study of Obesity and Overweight, sponsored by Novo Nordisk A/S.
NCT03552757 is a Phase 3 study of Obesity and Overweight that has completed, run by Novo Nordisk A/S. The registered enrollment target is 1,210 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (48% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03552757, a Phase 3 study of Obesity and Overweight, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,210 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the participant will have talks with study staff about healthy food choices, how to be more physically active and what else the participant can do to lose weight. Overweight and obesity is associated with an increased risk of type 2 diabetes. Therefore, weight loss has shown to have a beneficial impact on the blood sugar levels. The participant will either get semaglutide or "dummy" medicine - which treatment the participant get is decided by chance. The participant will need to take 2 injections at the same time once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The study will last for about 1.5 years
Primary Outcome
Change in body weight (%) from baseline (week 0) to week 68 is presented. Results are based on the data from both in-trial and on-treatment observation periods. In-trial observation period: the uninterrupted time interval from the start of randomisation (week 0) to last trial-related subject-site contact (week 75). On-treatment observation period: the interval from the date of first trial product administration (week 0) to the date of last trial product administration (week 68) plus a 2-week fol
Conditions Studied
Interventions
- DRUG Semaglutide 1.0 mg
- DRUG Semaglutide 2.4 mg
- DRUG Placebo I (Semaglutide)
- DRUG Placebo II (Semaglutide)
Study Locations (20)
California
- Novo Nordisk Investigational Site - Buena Park
- Novo Nordisk Investigational Site - Concord
- Novo Nordisk Investigational Site - Fresno
- Novo Nordisk Investigational Site - Lomita
- Novo Nordisk Investigational Site - Los Angeles
- Novo Nordisk Investigational Site - Mission Hills
- Novo Nordisk Investigational Site - Spring Valley
- Novo Nordisk Investigational Site - Tarzana
Florida
- Novo Nordisk Investigational Site - Clearwater
- Novo Nordisk Investigational Site - Jacksonville
- Novo Nordisk Investigational Site - Jacksonville
- Novo Nordisk Investigational Site - Kissimmee
- Novo Nordisk Investigational Site - St. Petersburg
- Novo Nordisk Investigational Site - Tampa
Georgia
- Novo Nordisk Investigational Site - Alpharetta
- Novo Nordisk Investigational Site - Atlanta
- Novo Nordisk Investigational Site - Roswell
Illinois
- Novo Nordisk Investigational Site - Chicago
- Novo Nordisk Investigational Site - Chicago
Colorado
- Novo Nordisk Investigational Site - Golden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,210 participants |
| Start Date | 2018-06-04 |
| Est. Completion | 2020-05-01 |
| Phase | Phase 3 |
What the finished NCT03552757 record still lists
NCT03552757 is an interventional study that assigns participants to a tested intervention. Its 1,210 participants enrollment target places it among the larger protocols in the corpus, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (48% higher).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Semaglutide 1.0 mg is the first listed.
NCT03552757 names 20 study sites across 5 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03552757 about?
NCT03552757 is a clinical study titled "Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity". This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the participant will ha...
What is the current status of trial NCT03552757?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,210 participants. The study started on 2018-06-04. Estimated completion is 2020-05-01.
What conditions does trial NCT03552757 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT03552757?
The interventions under investigation include: Semaglutide 1.0 mg (DRUG), Semaglutide 2.4 mg (DRUG), Placebo I (Semaglutide) (DRUG), Placebo II (Semaglutide) (DRUG).
Who is sponsoring clinical trial NCT03552757?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03552757 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03552757's enrollment target sits among peer trials
1,210 65th of 1053 higher than 989 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI